Patents by Inventor Alfredo ZURLO

Alfredo ZURLO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING A LATENT HIV-1 INFECTION USING NON-CODING DEOXYRIBONUCLEIC ACIDS
    Publication number: 20230310594
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 5, 2023
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • Methods of treating a retroviral infection
    Patent number: 11583581
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 11578331
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 14, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Combination comprising immunostimulatory oligonucleotides
    Publication number: 20210010003
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Application
    Filed: February 18, 2020
    Publication date: January 14, 2021
    Applicant: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • MEANS FOR THE TREATMENT OF HIV
    Publication number: 20200230234
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Application
    Filed: September 21, 2016
    Publication date: July 23, 2020
    Applicant: MOLOGEN AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO, Ole SCHMELTZ SOGAARD, Martin TOLSTRUP, Rasmus OFFERSEN
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 10604760
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 31, 2020
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 10487333
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 26, 2019
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • COMBINATION COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
    Publication number: 20190316134
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Applicant: Mologen AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO
  • COMBINATION COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
    Publication number: 20180251767
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Application
    Filed: September 9, 2016
    Publication date: September 6, 2018
    Applicant: MOLOGEN AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO